Plain-English translation of NCT03695978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is observing how well three blood clotting medications—Nuwiq, Octanate, and Wilate—work in patients with severe hemophilia A who are newly starting treatment or have only had minimal prior treatment. Rather than testing something new in a controlled way, researchers are collecting real-world information about how these medications are actually used, how effective they are at preventing bleeding, and what side effects patients experience.
Hemophilia A is a rare disease, so doctors don't have as much real-world information as they'd like about how well these medications work in young children who are just starting treatment. This study aims to fill that gap and help doctors better understand the best ways to use the medication, including how often to give it and when to start treatment.
You likely qualify if…
You likely don't qualify if…
You would continue receiving the medication your doctor has already prescribed (one of the three options), and the study team would collect information from your medical records about how you're doing—including how often you bleed, any side effects, and whether your body develops resistance to the treatment. This is not an interventional trial where you'd receive something experimental; instead, researchers are simply documenting your regular clinical care over time to gather real-world evidence.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States